Ensuring Lasting Smiles Act
The Ensuring Lasting Smiles Act would require group health plans and both group and individual health insurance issuers to cover medically necessary outpatient and inpatient services for the diagnosis and treatment of congenital anomalies or birth defects that primarily affect the eyes, ears, teeth, mouth, or jaw. Covered services include reconstructive procedures, related diagnostic and follow-up care, and adjunctive dental, orthodontic, and prosthodontic treatment needed to restore function or approximate normal appearance. The bill also requires coverage for complications arising from such treatment and for secondary conditions tied to the underlying anomaly.
The bill defines congenital anomaly or birth defect broadly as a structural or functional anomaly that develops prenatally and may be identified before birth, at birth, or later in life. It expressly excludes cosmetic surgery that is not tied to a medical determination of a congenital anomaly or birth defect. The bill would add parallel requirements to the Public Health Service Act, ERISA, and the Internal Revenue Code, and it would take effect for plan years beginning on or after January 1, 2026. It also directs health plans and issuers to provide notice of the new coverage requirements to participants and beneficiaries.
In addition to the coverage mandate, the bill requires the Secretary of Health and Human Services to study provider network adequacy and report to Congress by December 31, 2027. That report must evaluate whether networks are sufficient and accessible for these services and assess changes in out-of-pocket costs and overall procedure costs after the new coverage rules take effect.
The general sentiment reflected in the bill’s sponsorship is strongly supportive and bipartisan, with a large group of senators from both parties listed as cosponsors. The bill’s structure suggests a consensus around improving access to medically necessary reconstructive and dental-related care for people born with craniofacial and related anomalies. No committee transcript or vote record was provided, so there is no recorded floor or committee debate to indicate opposition in the available materials.
The main point of potential contention is the scope of required coverage, especially how broadly medically necessary treatment is defined and how plans will distinguish covered reconstructive care from excluded cosmetic surgery. Insurers and employers could also focus on cost-sharing rules, administrative compliance, and the possible impact on premiums or network adequacy, while patient advocates are likely to emphasize access, continuity of care, and the need for specialized providers.
The bill would amend the Public Health Service Act, ERISA, and the Internal Revenue Code to create a uniform federal coverage requirement for medically necessary treatment of congenital anomalies or birth defects affecting the eyes, ears, teeth, mouth, or jaw. It would require plans and issuers to cover specified reconstructive, dental, orthodontic, prosthodontic, diagnostic, and follow-up services, subject to cost-sharing no more restrictive than that applied to substantially all other medical and surgical benefits. It would also require participant notice beginning no later than January 1, 2026, and would direct HHS to study provider network adequacy and patient cost impacts.
The available context suggests broad, bipartisan support for the bill’s purpose of improving access to medically necessary care for congenital anomalies and birth defects. The sponsor list includes senators from both parties, indicating the measure is framed as a patient-access and coverage equity bill rather than a partisan policy change. No votes or committee transcript excerpts were provided, so there is no evidence in the record supplied here of organized opposition or divided committee sentiment.
The likely areas of contention are the breadth of the coverage mandate and the line between reconstructive treatment and excluded cosmetic surgery. Insurers, employers, and plan administrators may be concerned about compliance costs, premium effects, and how medical necessity will be determined in practice, especially for services involving dental, orthodontic, and prosthodontic care. Patient advocates and families affected by congenital anomalies are likely to support the bill’s broad coverage language and its attempt to prevent denials of medically necessary treatment.